Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

NCT00572637 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Lymphoma, Non-Hodgkin

Interventions

DRUG: CEP-18770

Sponsor

Ethical Oncology Science